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Distinguishing the Contribution of Type 1 Pili from That of Other
QseB-Misregulated Factors when QseC Is Absent during Urinary Tract
Infection
Maria Kostakioti,a Maria Hadjifrangiskou,a Corinne K. Cusumano,a Thomas J. Hannan,d James W. Janetka,c and Scott J. Hultgrena,b
Department of Molecular Microbiology & Microbial Pathogenesis,a Center for Women’s Infectious Disease Research,b Department of Biochemistry and Molecular
Biophysics,c and Department of Pathology & Immunology,d Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA
Urinary tract infections (UTI), primarily caused by uropathogenic Escherichia coli (UPEC), are one of the leading bacterial infec-
tions due to their high frequency and rate of recurrence. Both type 1 pilus adhesive organelles (fim) and the QseC sensor kinase
have been implicated in UPEC virulence during UTI and have been individually reported to be promising drug targets. Deletion
of qseC leads to pleiotropic effects due to unregulated activation of the cognate response regulator QseB, influencing conserved
metabolic processes and diminishing expression of virulence genes, including type 1 pili. Here, we discern the type 1 pilus-de-
pendent and -independent effects that contribute to the virulence attenuation of a UPEC qseC deletion mutant in a murine
model of experimental UTI. We show that although aqseCmutant restored for type 1 pilus expression regains the ability to
colonize the host and initiate acute infection up to 16 h postinfection, it is rapidly outcompeted during acute infection when coi-
noculated with a wild-type strain. As a result, this strain has a diminished capacity to establish chronic infection. A prophylactic
oral dose of a FimH small-molecular-weight antagonist (ZFH-02056) further reduced the ability of the qseCmutant to establish
chronic infection. Thus, loss of QseC significantly enhances the efficacy of ZFH-02056. Collectively, our work indicates that type
1 pili and QseC become critical in different infection stages, and that dual targeting of these factors has an additive effect on ab-
lating UPEC virulence.
Urinary tract infections (UTI) are one of the most commonbacterial infections, afflicting primarily women and account-
ing for more than 3.5 billion dollars in health care costs in the
United States alone (18). Approximately one out of three patients
with a UTI will experience recurrence (rUTI) within 6 to 12
months, and in 60% of these cases, rUTI is induced by the same
bacterial strain that caused the original infection (15, 28), indicat-
ing the presence of a possible intestinal and/or extraintestinal res-
ervoir within the host (14, 36, 38, 39). Nearly 85% of community-
acquired UTIs are caused by uropathogenic Escherichia coli
(UPEC) (18), which can overcome host defenses in part by invad-
ing bladder epithelial cells (14, 35). Numerous bacterial factors
have been shown to be important in UPEC UTIs, including cap-
sule, iron acquisition systems, toxins, a virulence plasmid, tRNAs,
pathogenicity islands, and colonization factors (1, 7, 10, 20, 22, 23,
34, 50, 51, 53). Adhesive pili assembled by the chaperone/usher
pathway (CUP), such as type 1 pili, contain adhesins at their tips
that are thought to play an important role in host-pathogen inter-
actions (48). Each sequenced UPEC strain has been found to en-
code a multitude of CUP operons (7, 23, 49). Some CUP adhesins
are known to recognize specific receptors with stereochemical
specificity (26, 45). For example, FimH, the type 1 pilus tip adhe-
sin, has been shown to bindmannosylated glycoproteins, aswell as
N-linked oligosaccharides on 1 and 3 integrins and the pattern
recognition receptor TLR4, which are expressed throughout the
luminal surface of human and murine bladders (5, 13, 26, 33, 45,
46, 55). These FimH-mediated interactions facilitate bacterial col-
onization and invasion, triggering apoptosis and exfoliation (35,
38) and inducing elevated levels of cyclic AMP (cAMP) (4). Upon
internalization, UPEC are exocytosed in a TLR-4-dependent pro-
cess (4); however, bacteria can escape into the host cell cytoplasm,
where they are able to subvert expulsion and innate defenses by
replicating into biofilm-like intracellular bacterial communities
(IBCs) (2, 29). Subsequently, UPEC disperse from the IBC, escape
into the bladder lumen, and reinitiate the process by binding and
invading neighboring uninfected epithelial cells (29). The murine
model has revealed two potential outcomes of these acute events,
either resolution of infection with the establishment of quiescent
intracellular reservoirs that can serve as seeds for recurrence (38)
or the establishment of chronic bladder infection (chronic cysti-
tis) (21). Chronic cystitis is characterized by persistent, high-titer
bacteriuria (104 CFU/ml), as well as high-titer bacterial bladder
burdens at2 weeks postinfection (wpi) and evidence of chronic
bladder inflammation (11, 21). The ability of UPEC to form IBCs
appears to be a critical determinant of disease outcome, as a pre-
vious study suggests that a higher number of IBCs formed during
the acute stages of infection precedes the development of chronic
cystitis (43). Thus, differing selection pressures and bacterial pop-
ulation dynamics, as well as niche residence and population bot-
tlenecks, determine the ability of UPEC to survive and cause an
acute infection and/or persist long term in the urinary tract as a
chronic extracellular infection (chronic cystitis) (21, 43).
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The IBC pathogenic cascade, which has been characterized in a
murine model of infection (2, 27, 29) and has been extensively
documented in samples from human clinical studies (17, 42), is
FimH dependent (52). It has been shown that the fimH gene is
under positive selection in human clinical isolates of UPEC (6),
further supporting its role in human disease. Thus, it has been
reported that type 1 pili fulfill the molecular Koch’s postulates of
microbial pathogenesis (44). Type 1 pili are encoded by the fim
gene cluster, and their expression is directed by a phase-variable
promoter (fimS), which facilitates a switch between piliated and
nonpiliated bacterial states (30). UPEC populations are typically
heterogeneous in terms of pilus expression, consisting of bacteria
that are observed by transmission electron microscopy to be bald
or lightly, moderately, or highly piliated (40). The ratio of each
piliated fraction shifts depending on the environmental niche.
Studies investigating the expression of type 1 pili revealed that
UPEC associated with epithelial cells are highly piliated, consis-
tent with the critical role of type 1 pili in colonization of the
urothelium (26, 33, 54, 55). In contrast, the fimS promoter in
bacteria recovered from urine samples of patients has been shown
to be predominantly in the OFF phase (32). Regulation of fimS
phase variation is controlled by the FimB, FimE, and FimX recom-
binases, the expression of which is influenced by numerous regu-
latory factors (16, 20, 30). We recently identified the QseBC two-
component system as one of the factors implicated in the
regulation of several CUPs in UPEC, including type 1 pili (19, 31).
In a UPEC mutant lacking the sensor kinase QseC, the fim pro-
moter is found primarily in the OFF orientation, resulting in re-
duced type 1 pilus expression, an effect that stems from uncon-
trolled activation of the QseB response regulator in this mutant
(31). In addition to influencing type 1 pilus expression in the
absence of qseC, overactive QseB (31) dysregulates conserved cel-
lular pathways and impacts several other virulence-associated
genes, resulting in UPEC attenuation (19, 31).
While the effects of disruption of type 1 pilus production on
UPEC pathogenesis are fairly well understood (6, 8, 24, 52) and
likely explain at least some of the attenuation of theqseCmutant,
the contributions of QseB-misregulated factors in the attenuation
of qseC, independent of type 1 pili, are unknown. Therefore, in
this study we disengaged type 1 pili from QseBC control to
determine the role of other QseB-misregulated factors in acute
and chronic stages of bladder infection. By locking the invert-
ible fim promoter element in the ON orientation, we restored
type 1 pilus expression in the qseC mutant. The resulting
strain, UTI89qseC_LON (LON indicates locked in the ON ori-
entation), was rescued in its ability to cause acute UTI but was
rapidly outcompeted by wild-type (wt) UTI89 during acute com-
petitive infection studies and was less efficient at causing chronic
cystitis. Thus, despite expression of type 1 pili, the QseB-misregu-
lated processes in the qseC mutant decrease bacterial fitness for
acute infection and reduce the ability of UPEC to develop chronic
cystitis. We then used small-molecular-weight FimH inhibitors,
also known as mannosides, as molecular scalpels to show that
transiently blocking FimH function during infection, by oral pro-
phylactic administration, further impeded the ability of qseC to
cause chronic cystitis compared to qseC alone. Collectively, our
studies extend our understanding of the basis of qseC attenua-
tion, distinguishing the effect of type 1 pili from that of other
QseB-misregulated factors during the course of infection, and
support that simultaneously targeting QseC and type 1 pili repre-
sents a promising avenue for potentiating therapeutics against
UPEC.
MATERIALS AND METHODS
Strains, constructs, and growth conditions. UTI89 is a human cystitis
isolate that is highly virulent in a mouse model of UTI (36). UTI89_LON
and UTI89qseC_LONwere created using  Red recombinase and prim-
ers LON_L (TAAAAAGAGAAGAAGCTTGATTTAACTAATTGATAAT
AAAGTTAAAAAAGTGTAGGCTGGAGCTGCTTC) and LON_R
(CGATGCTTTCCTCTATGAGTCAAAAGAGATCTAATTGTCTTGT
ATTTATTTGCATATGAATATCCTCCTTAG) so as to mutate 5 out of 9
nucleotides in the left invertible repeat (LIR) of the fim promoter in the
chromosome (37) (the wt LIR sequence 5=-TGGCCCCAA-3= was mu-
tated to 5=-GAGATCTAA-3= and is underlined in the sequences above).
Chromosomally marked LON strains were constructed as shown in the
Fig. 2A schematic but without inducing excision of the Kan cassette (the
last step of the schematic). Similarly, chromosomally marked UTI89 and
UTI89qseC strains were constructed with the Kan resistance cassette in
the-att or qseC locus, respectively. All strains have previously been tested
and behave identically to their nonmarked counterparts. Bacteria were
incubated in Luria-Bertani (LB) medium at 37°C for 4 h under shaking
conditions, subcultured (1:1,000) in fresh LB medium, and incubated
statically at 37°C for 18 h.
Mouse infections. All procedures involving mice were performed in
compliance with current federal guidelines and institutional policies at
Washington University in Saint Louis and ensured the proper and hu-
mane treatment of animals. FemaleC3H/HeNmice (Harlan), 7 to 9weeks
old, were used for all studies described below, and in each case mice were
infected with 107 bacteria.
Short-term infections.Mice were transurethrally infected with bacte-
ria carrying the green fluorescent protein (GFP)-expressing plasmid
pANT4 (9) as previously described (31), and they were sacrificed at 1 and
3 h postinfection (hpi). Bladders were aseptically removed, homogenized,
and plated for total bacterial enumeration or gentamicin treated to deter-
mine intracellular bacterial titers. The experiment was repeated 3 times,
and statistical analysis was performed using two-tailed Mann-Whitney
tests (P 0.05 was considered significant).
Ex vivo gentamicin assay. Bladders were bisected and washed 3 times
in 500l phosphate-buffered saline (PBS). The washes were collected and
plated for CFU enumeration to determine luminal bacteria.Washed blad-
ders were incubated for 90 min at 37°C with 100 g/ml gentamicin to kill
adherent extracellular bacteria. Following washes (3) with PBS, blad-
ders were homogenized in 1 ml PBS and plated to determine intracellular
bacterial titers. The two-tailedMann-Whitney test (P 0.05)was used for
statistical analysis.
Acute infection studies. Mice were transurethrally infected with 107
bacteria carrying the plasmid pANT4 as previously described (31). Exper-
iments were repeated three times and statistically analyzed using the two-
tailed Mann-Whitney test (P 0.05 was considered significant).
Long-term infection studies. Mice were infected with chromo-
somally marked strains of wt UTI89, UTI89_LON, UTI89qseC, or
UTI89qseC_LON. Mice were sacrificed at 2 weeks postinfection
(wpi), and organs were processed for CFU enumeration on LB-kana-
mycin agar plates. The experiment was repeated 2 times. Cumulative
data from all experiments are presented.
Competition assays. Cohorts of 10 mice were used per time point.
Bacterial inocula were prepared such that they comprised 50%
UTI89_LON and 50% UTI89qseC_LON (Kanr) in a total of 3 107 to
4  107 bacteria per 50 l, and the inocula were transurethrally intro-
duced in each mouse. Mice were sacrificed at 6, 16, 30, 48, and 72 hpi,
and organs were processed for CFU enumeration on LB and LB-Kan
agar plates. To account for possible variation due to antibiotic resis-
tance, experiments were repeated using UTI89_LON (Kanr) and
UTI89qseC_LON. The experiment was repeated 3 times. Cumulative
Type 1 Pilus-Independent Role of QseBC during UTI
August 2012 Volume 80 Number 8 iai.asm.org 2827
 o
n
 M
arch 31, 2014 by W
ashington University in St. Louis
http://iai.asm
.org/
D
ow
nloaded from
 
data from all experiments are presented. Statistical analysis was per-
formed using the Wilcoxon matched-pairs signed-rank test.
Mannoside studies.One hundredl of a 10mg/ml (50mg/kg of body
weight) solution of ZFH-02056 {IUPAC name: N1,N3-dimethyl-5-[4-]
(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-
2-yl[oxyphenyl]benzene-1,3-dicarboxamide} was administered to each
mouse by oral gavage 30 min prior to bacterial inoculation. Control mice
were gavaged with 100 l of PBS 30 min prior to bacterial inoculation.
Mice were euthanized at 2 and 4 wpi, and organs were processed for CFU
enumeration.
IBC enumeration by confocal microscopy. For IBC enumeration,
mice were infected with fluorescent bacteria carrying the GFP-plasmid
pANT4 as described above for acute infections. Bladders excised from
infected animals were treated for confocal microscopy as previously de-
scribed (53). Briefly, bladders were bisected, splayed, and fixed in 4%
paraformaldehyde overnight at 4°C. Fixed bladders were washed and
counterstained for 20 min with the nuclear ToPro3 (Molecular Probes)
stain and rhodamine-conjugated wheat germ agglutinin to outline the
facet cells (1:700 dilution for each). For IBC enumeration, the entire blad-
der was scanned using a Zeiss LSM 510 Meta laser scanning inverted
confocal microscope (Thornwood).
Immunoblotting, HA, and phase assays. Bacteria were grown stati-
cally in LB for 18 h at 37°C. Immunoblotting (using anti-type 1 pilus
antibody), hemagglutination (HA), and phase assays were performed on
normalized cells (optical density at 600 nm [OD600] of 1) as previously
described (25, 31).
qPCR analyses. RNA extraction, DNase treatment, and reverse tran-
scription were performed using reagents and methods as reported by
Kostakioti et al. (31). Relative transcript abundance was determined by
quantitative PCR (qPCR) as previously described (31) using aceB-specific
(19) or qseB-specific (31) primers.
RESULTS
Deletion of QseC impairs the ability of UPEC to colonize and
invade the bladder. We have previously shown that deletion of
qseC in UTI89 leads to reduced bladder bacterial titers during the
acute stages of infection (6 and 16 h postinfection) in a cystitis
murine model (31). Given that type 1 pili are critical for bladder
adherence and invasion (33, 35) and are significantly reduced in
the absence ofQseC,we rationalized that the in vivo attenuation of
UTI89qseC could be, at least partly, attributed to reduced type 1
pilus-mediated colonization and invasion of the bladder. Thus, we
assessed the ability of UTI89qseC to adhere to and invade the
bladder epithelium compared to the parent strain. Female C3H/
HeNmice were transurethrally inoculated with 107 wild-type (wt)
UTI89 or UTI89qseC, and bacterial colonization and invasion
were assessed at 1 and 3 h postinfection (hpi), time points previ-
ously shown to be suitable for studying the invasion events in vivo
(29, 33, 35). Enumeration of CFU recovered from infected blad-
ders indicated that compared to wt UTI89, UTI89qseC had sig-
nificantly lower overall bacterial titers (which include both intra-
cellular and luminal populations) at both time points (Fig. 1A).
Treatment of infected bladders with gentamicin to eradicate the
luminal bacterial population while leaving the intracellular popu-
lation unharmed revealed decreased intracellular numbers for
UTI89qseC (Fig. 1B). Despite the observed reduced internaliza-
tion of UTI89qseC, the number of luminal UTI89qseC bacteria
was not higher but rather was comparable to wt UTI89 luminal
populations (Fig. 1B); given the reduced expression of type 1 pili
by UTI89qseC, these data suggest that reduced adherence of
UTI89qseC leads to faster clearance by micturition. Thus, our
data indicate that deletion of qseC affects the ability of UTI89 to
initiate infection in part by compromising its ability to colonize
and invade the host bladder.
Expression of type 1 pili rescues the adherence properties of
UTI89qseC in vitro but does not influence other qseC-re-
lated defects. Our findings demonstrate that attenuation of
UTI89qseC is linked to reduced bacterial internalization due to
decreased type 1 pilus production. We therefore investigated
whether restoration of type 1 pilus expression alone would be
sufficient to overcome the in vivo defects of UTI89qseC.We have
previously reported that in the absence of QseC, the phase-vari-
able fim promoter driving type 1 pilus expression, fimS, is primar-
ily switched to the OFF orientation (31). We thus locked fimS in
the ON orientation in the chromosome of wt UTI89 and
UTI89qseC to attain expression of type 1 pili independently of
QseC (Fig. 2A). UTI89_LON and UTI89qseC_LON exhibited
comparable mannose-sensitive hemagglutination (HA) proper-
ties, which were higher than that of the wt UTI89 because the
inversion of the promoter to the OFF state can no longer occur
(Fig. 2B). Consistent with this, Western blot analyses probing for
FimA, themajor type 1 pilus subunit, verified that the level of type
1 pilus production in UTI89qseC_LON is comparable to that of
UTI89_LON, but again it is higher than that of wt UTI89 (Fig.
2C). Electron microscopy revealed that the resulting strains,
UTI89_LON and UTI89qseC_LON, were not hyperpiliated,
FIG1 UTI89qseC has a defect in bladder invasion. (A) Bladder titers at 1 and
3 hpi showing bacterial numbers recovered from bladders infected with
UTI89qseC or wt UTI89. (B) Bacterial titers recovered from gentamicin-
treated bladders (intracellular population) after washing 3 times with PBS to
remove the extracellular, adherent bacteria (luminal population). Data from 3
independent experiments are shown (*, P  0.02; **, P  0.003; ***, P 
0.0001; all by two-tailed Mann-Whitney).
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FIG 2 Restoring production of type 1 pili in UTI89qseC does not influence other qseC-mediated defects. (A) Schematic showing the strategy used to
lock the phase-variable fim promoter in the ON orientation. LIR, left invertible repeat within the fim promoter; RIR, right invertible repeat within the fim
promoter; LIR*, mutated left invertible repeat of the fim promoter. (B and C) Hemagglutination assays and Western blot analyses depicting restoration
of type 1 pilus expression in UTI89qseC locked-ON strain (qseC_LON). (D) Locking the fim promoter ON does not interfere with the QseB-mediated
dysregulation in the qseC deletion mutant. Relative fold change of qseB and aceB in UTI89_LON and UTI89qseC_LON compared to UTI89 and
UTI89qseC, measured by qRT-PCR. Values are normalized to the 16S rrsH gene. (E) Assessment of curli production on YESCA-CR agar verifies that,
similar to UTI89qseC, UTI89qseC_LON remains defective for curli expression, exhibiting a white and smooth morphotype. Graphs depict averages of
three independent experiments; error bars denote standard errors of the means. Statistical analysis was performed by unpaired two-tailed Student’s t test
(*, P  0.05; **, P  0.0099; ***, P  0.0001).
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rather a larger population of piliated versus nonpiliated bacteria
was observed compared to wt UTI89 (data not shown).
In addition to defects in type 1 pilus expression, deletion of
qseC results in perturbation of central cellular processes due to
aberrant upregulation and activation of the QseB response regu-
lator (19, 31). This prompted us to verify that restoration of type 1
pilus expression does not affect theQseB-mediated dysregulation.
We first performed quantitative reverse transcription-PCR (qRT-
PCR) to probe the expression of qseB in the fim-locked-ON
(LON) strains compared towtUTI89 andUTI89qseC.We found
that the LON strains behaved similarly to their non-LON coun-
terparts, with UTI89qseC and UTI89qseC_LON exhibiting in-
creased qseB levels compared to both wt UTI89 and UTI89_LON
(Fig. 2D). These data suggest that themassive pleiotropy imparted
by QseB-mediated misregulation in the absence of QseC remains
unaffected upon restoration of type 1 pilus expression. To test this,
we examined the expression of AceB, ametabolic factor, and curli,
a bacterial amyloid, both known to bemisregulated in the absence
of QseC (19). We confirmed by qRT-PCR that aceB, which is
upregulated in UTI89qseC (19), displays elevated transcript lev-
els in UTI89qseC_LON compared to both UTI89 and
UTI89_LON (Fig. 2D), while curli expression was abolished,
which is the previously reported defect of UTI89qseC (Fig. 2E).
Curli formation can be assessed by growth on yeast extract/
Casamino Acids agar supplemented with the Congo red dye
(YESCA-CR), since curli bind CR, giving rise to red, dry, and
rough colonies (3). When grown under curli-inducing condi-
tions, UTI89qseC_LON had a white and smooth morphotype
on YESCA-CR medium similar to UTI89qseC and in contrast
to the red, dry, and rough curli-positive phenotype of UTI89
and UTI89_LON (Fig. 2E). As expected, based on these results,
production of the CsgG outer membrane pore, critical for se-
cretion of the curli components, was diminished in
UTI89qseC_LON but remained unaffected in UTI89_LON
(data not shown). These findings show that locking the fim
promoter in the ON orientation does not interfere with qseB
overexpression and the associated downstream defects im-
parted by the qseC deletion.
UTI89qseC_LON is restored for virulence in the acute in-
fection stages.We investigated whether restoration of type 1 pilus
expression would rescue the qseC phenotype during the acute
stages of infection. Our previous studies demonstrated that de-
letion of qseC results in reduced bladder titers and diminished
IBC formation at 6 and 16 hpi (31). Since type 1 pili are essen-
tial for attachment, invasion, and IBC formation (52), we
tested the ability of UTI89qseC_LON to survive within the
urinary tract and form IBCs during these times. Mice were
infected with wt UTI89, UTI89qseC, UTI89_LON, or
UTI89qseC_LON, and bacterial invasion was evaluated at 1
hpi by gentamicin protection assays. UTI89_LON and
UTI89qseC_LON had comparable amounts of internalized
bacteria, in contrast to what was observed for UTI89qseC
(Fig. 3A). In contrast to UTI89qseC, the bacterial titers recov-
ered from UTI89qseC_LON-infected bladders were compa-
rable to those recovered for wt UTI89 and UTI89_LON at both
6 and 16 hpi (Fig. 3B). Similarly, UTI89qseC_LON formed
IBCs as efficiently as wt UTI89 and UTI89_LON (Fig. 3C).
Thus, restoring expression of type 1 pili in the absence of QseC
is sufficient for rescuing IBC formation and survival within the
bladder at the acute infection stages.
UTI89qseC_LON is outcompeted by UTI89_LON within
the host. To investigate whether QseB-mediatedmisregulation in
the UTI89qseC_LON strain imparted a fitness disadvantage in-
dependent of the conferred type 1 piliation defect in UPEC acute
pathogenesis, we monitored the infection outcome in mice coin-
fected with equal bacterial loads of differentially marked
FIG 3 UTI89qseC_LON is restored for virulence at the early and acute in-
fection stages. (A) Bacterial numbers recovered from infected bladders at 1 hpi
showing that UTI89qseC_LON invades the bladder as efficiently as the par-
ent strain. (B and C) Bacterial titers and IBC numbers at 6 and 16 hpi reveal
that UTI89qseC_LON can survive inside the host at levels comparable to wt
UTI89 during the acute stages of infection. Data from 3 independent experi-
ments are shown (*, P 0.04; **, P 0.009; ***, P 0.0003; all by two-tailed
Mann-Whitney test).
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UTI89_LONandUTI89qseC_LON strains during a 72-h period,
marking the acute and subacute stages. Our data revealed that
UTI89qseC_LON began exhibiting a fitness disadvantage as
early as 6 hpi in the presence of UTI89_LON, as indicated by a
median competitive index (CI) of 0.1860 (CIs ranged from 0.0496
to 6.951) (Fig. 4A). The fitness disadvantage was more prominent
at the later stages of infection, with the CI median dropping 16-
fold, from 0.1860 to a value of 0.0115 at 16 hpi, with a range of
0.000074 to 0.2368 (Fig. 4A). These data suggest that restoration
of type 1 pili does not suffice for complete restoration of in vivo
fitness.
UTI89qseC_LON is less efficient in establishing chronic
cystitis.We used enumeration of bladder titers at 2 weeks postin-
fection (wpi) as a surrogate marker of chronic cystitis to deter-
mine whether QseB-mediated misregulation reduces the ability
of UPEC to establish chronic cystitis, even in the presence of
type 1 pilus expression. Cohorts of female C3H/HeNmice were
inoculated with wt UTI89, UTI89qseC, UTI89_LON, or
UTI89qseC_LON, and CFU were enumerated at 2 wpi. Our
findings demonstrated that, compared to wt UTI89, mice in-
fected with UTI89qseC had significantly lower titers by 2 wpi,
with only 2 out of 20 mice (10%) displaying high bladder titers
(104) indicative of chronic cystitis (Fig. 4B). These results are
consistent with the lower bacterial burden observed for
UTI89qseC at the acute infection stages (Fig. 3). The LON
strainswere significantlymorecompetent inestablishingchroniccys-
titis, due to their inability to revert fimS in the OFF orientation, than
their non-LON counterparts. UTI89qseC_LON was as efficient as
wtUTI89 indeveloping chronic cystitis.However, significantly fewer
mice infectedwithUTI89qseC_LONhadhigh bacterial titers indic-
ative of chronic cystitis (51.7%) compared to the mice infected with
UTI89_LON (70.0% developed chronic infection) (Fig. 4B). These
findings argue that QseB-mediated misregulation in the absence of
QseC imparts a fitness disadvantage independent of the conferred
type 1 piliation regulatory defects.
The effect of FimH inhibitors that blunt type 1pilus function
is potentiated by deletion of qseC. Deletion of qseC reduces but
does not abolish expression of type 1 pili (31). We rationalized
that if we temporarily blunt type 1 pilus function in the qseC
mutant during the acute infection stage, we will exacerbate the
inability of this mutant to establish chronic infection. Com-
pounds ZFH-02056 andZFH-04269 (mannosides) bindwith high
affinity to the mannose-binding pocket of the FimH adhesin and
thus are potent inhibitors of type 1 pilus function (11). Specifi-
cally, oral administration of ZFH-02056 and ZFH-04269 signifi-
cantly reduces bacterial titers in chronically infectedmice within 6
h (11). We used compound ZFH-02056 as a molecular scalpel to
temporarily blunt FimH function in wt UTI89 and UTI89qseC
early in infection and assess long-term infection outcome. Mice
were pretreated with one dose of 50 mg/kg ZFH-02056 and in-
fected 30 min after treatment with wt UTI89 or UTI89qseC.
Compound ZFH-02056 becomes bioavailable in the bladder
within 30 min of oral delivery and at this dosage is sustained for 6
h above the MIC (11). Mice treated with PBS prior to infection
were included as controls. Bladder bacterial titers were enumer-
ated at 2wpi to estimate the propensity for chronic infection. Even
though ZFH-02056 is bioavailable at the dose delivered in the
bladder for only 6 h (11), we observed that this single dosing
significantly affected the course of infection 2 wpi. Compared to
nontreated mice, at 2 wpi there was a 2-log reduction in CFU in
mannoside-treated mice infected with wt UTI89 (Fig. 5, UTI89
versus UTI89_MAN). Thus, this single-dose mannoside treat-
ment of wt UTI89 resulted in the same degree of attenuation ob-
served with UTI89qseC; both had a similar reduction in CFU
(Fig. 5, UTI89_MAN versus UTI89qseC). Notably, in manno-
side-treated animals infected with UTI89qseC, bacterial reduc-
tion was further enhanced, as indicated by an additional 1.5-log
drop in CFU, compared to mannoside-treated animals infected
with wt UTI89 (Fig. 5, UTI89_MAN versus UTI89qseC_MAN).
Our findings strongly indicate that dual targeting of QseC and
FIG 4 Restored type 1 pilus expression cannot sustain wild-type persistence of the qseC deletion mutant inside the host. (A) Competition assays showing that
UTI89qseC_LONhas a survival disadvantage compared to the parent strain and is rapidly cleared from the host bladder. Competitive index (CI) was calculated
by dividing the ratio of UTI89qseC_LON versus UTI89_LON titers by the ratio of the corresponding inocula. A CI of1 indicates that UTI89qseC_LON has
a fitness disadvantage compared to UTI89_LON. Data from 3 independent experiments are shown (*, P 0.03; **, P 0.005; ***, P 0.0009; all byWilcoxon
matched-pairs signed-rank test). (B)Graphdepicting the bladder bacterial titers recovered at 2wpi.Data from3 independent experiments are shown (*,P 0.03;
**, P 0.005; ***, P 0.0009; all by two-tailed Mann-Whitney test).
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type 1 pili could have an additive effect, thus potentiating bacterial
clearance from the bladder.
DISCUSSION
UPEC is the primary cause of UTI and is one of themost common
bacterial infections afflicting the humanpopulation due to its high
rate of occurrence and recurrence (14, 18). Among the patients
experiencing acute UTI symptoms, approximately one-third will
present with a recurrent infection within 6 to 12 months, while
othersmay experience other debilitating sequelae, such as chronic
infections or, in more severe cases, pyelonephritis, systemic infec-
tion, and death (14, 18, 28). The ability of UPEC to persist in
multiple niches in the urinary tract is responsible, at least in part,
for these disease outcomes (21, 28, 38, 43). Studies supporting this
have shown that UPEC can establish chronic infection (21) or
latently persist within the underlying epithelium, forming quies-
cent intracellular reservoirs (QIRs) that can reinitiate infection as
the epithelium layers mature (38). These disease outcomes seem
to be at least partly dependent on the number of IBCs formed (43).
Given the frequency of recurrent UTIs, the rapid emergence and
dissemination of antibiotic-resistant strains, and the potentially
harmful effects of suppressive antibiotic therapy to prevent recur-
rences (12, 47), the identification of new strategies to combat or
prevent UTIs becomes imperative. Here, we focus on distinguish-
ing the effects of two factors, type 1 pili and QseC, which not only
have been individually proposed to be ideal drug targets due to
their effects on UPEC virulence, but also have been shown to be
linked via a regulatory cascade that leads to fim misregulation
upon qseC deletion.
Type 1 pili and QseC have been extensively implicated in
UPEC virulence. Type 1 pili physically participate in the interac-
tions that lead to host colonization and establishment of infection,
while the QseC sensor kinase influences numerous cellular pro-
cesses that in turn affect virulence-associated factors, including
type 1 pili (19, 31, 33, 35, 51, 52). In this study, we show that
restoring type 1 pilus expression in the absence of qseC rescues the
adherence and invasion defects of this mutant and restores its
ability to properly form IBCs inside the host during the acute
infection stages. Thus, attenuation of UTI89qseC is largely
linked to reduced expression of type 1 pili, which decreases the
population of internalized bacteria. Of note, locking the fim pro-
moter in theONorientation shifted the overall population toward
piliated bacteria without yielding more pili per cell, which indi-
cates that the levels of pili on the bacterial surface are not exclu-
sively a function of phase variation but also are a function of tran-
scriptional and/or posttranscriptional regulation. Our studies
show that by shifting the population toward piliated bacteria, the
LON strains aremore efficient at colonizing and invading the host
than their non-LON counterparts, leading to more bacteria being
internalized, which is likely perpetuatedwith every IBC cycle. This
explains the higher levels of colonization in the LON bacteria at 2
wpi compared to the non-LON counterparts, as a previous study
demonstrated an association between the number of IBCs formed
during acute infection and the development of chronic cystitis
(21, 43). Interestingly, although UTI89qseC_LON is enhanced
in its ability to cause chronic infection compared to UTI89qseC,
it is still significantly less fit for establishing chronic cystitis than
UTI89_LON. We have found that the establishment of chronic
cystitis is dependent on host-pathogen interactions within the
first 24 h of acute infection (21, 43). Indeed, although
UTI89qseC_LON alone does not have a defect during acute
infection in single-infection experiments, it is rapidly outcom-
peted by UTI89_LON in the bladder when coinoculated with
this strain. Thus, QseB-mediated misregulation in the absence
of QseC results in a significant defect in sustaining infection
and establishing chronic cystitis, even when type 1 piliation is
restored. These data suggest that simultaneous inactivation of
these factors have an additive effect on interfering with the
onset of chronic UTI.
Research aimed at the development of therapeutics for UTIs
has shown that compoundZFH-02056, an inhibitor of type 1 pilus
function, significantly reduces UPEC titers in the host bladder
when used as a treatment for chronic cystitis (11). The qseC dele-
tion leads to reduced but not abolished expression of type 1 pili
(31). We showed that pretreatment with one oral dose of ZFH-
02056 significantly reduced the ability of UTI89qseC to establish
chronic cystitis. Thus, drugs targeting QseC may potentiate man-
nosides in the treatment of UTI. Previous studies identified
LED209 as an inhibitor of the kinase activity of QseC (41). How-
ever, our studies have established that the defects of a qseC dele-
tionmutant are associatedwith the phosphatase function ofQseC,
the absence of which results in an overactive QseB response regu-
lator that cannot be dephosphorylated and deactivated (31). In
vitro analyses demonstrated that LED209 had no inhibitory effect
on the phosphatase activity of UPEC QseC and did not impact
virulence-associated gene expression in UPEC (see Fig. S1 in the
supplemental material). These data further indicate that it is the
phosphatase activity ofQseC that needs to be targeted to attenuate
virulence, an area that we are currently exploring.
FIG 5 Coinhibition of type 1 pili and QseC as a prophylactic measure for UTIs.
Chart depicting the bladder CFU obtained at 2 wpi from mice pretreated with
mannoside and subsequently infectedwith eitherwtUTI89 orUTI89qseC (used
as a proxy for aQseC inhibitor). Significantly fewerCFU (1.5-log reduction)were
obtained from pretreated mice infected with UTI89qseC. The averages from 3
independent experiments are shown (**, P 0.01; ***, P 0.001; each by two-
tailedMann-Whitney). UTI89_MAN,mice pretreatedwithmannoside and chal-
lenged with wt UTI89; qseC_MAN, mice pretreated with mannoside and chal-
lenged with UTI89qseC; UTI89, mice pretreated with PBS and challenged with
wtUTI89; andqseC,micepretreatedwithPBSandchallengedwithUTI89qseC.
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Collectively, our work extends our understanding of the mo-
lecular basis of attenuation of UPEC qseC and shows that drugs
targeting QseC hold promise to further potentiate mannoside ef-
ficacy for the treatment and prevention of UTIs. Patients who
suffer from chronic or recurrent UTIs currently require suppres-
sive antibiotics which disrupt the normal flora, causing unwanted
side effects (14). The development of antivirulence agents would
provide an alternative prevention means with the potential to
eliminate UPEC colonization by effectively targeting both bacte-
rial attachment and invasion, but most importantly persistence
within the host, thereby greatly reducing the possibility of chronic
and nonretractable infections.
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